Immunotherapy after liver transplantation: Where are we now?

Background: There is limited evidence on the safety of immunotherapy use after liver transplantation and its efficacy in treating post-liver transplant hepatocellular carcinoma (HCC) recurrence.

Aim: To assess the safety of immunotherapy after liver transplant and its efficacy in treating post-liver transplant HCC recurrence.

Methods: A literature review was performed to identify patients with prior liver transplantation and subsequent immunotherapy. We reviewed the rejection rate and risk factors of rejection. In patients treated for HCC, the oncological outcomes were evaluated including objective response rate, progression-free survival (PFS), and overall survival (OS).

Results: We identified 25 patients from 16 publications and 3 patients from our institutional database (total = 28). The rejection rate was 32% ( = 9). Early mortality occurred in 21% ( = 6) and was mostly related to acute rejection (18%, = 5). Patients who developed acute rejection were given immunotherapy earlier after transplantation (median 2.9 years 5.3 years, = 0.02) and their graft biopsies might be more frequently programmed death ligand-1-positive (100% 33%, = 0.053). Their PFS (1.0 ± 0.1 mo 3.5 ± 1.1 mo, = 0.02) and OS (1.0 ± 0.1 mo 19.2 ± 5.5 mo, = 0.001) compared inferiorly to patients without rejection. Among the 19 patients treated for HCC, the rejection rate was 32% ( = 6) and the overall objective response rate was 11%. The median PFS and OS were 2.5 ± 1.0 mo and 7.3 ± 2.7 mo after immunotherapy.

Conclusion: Rejection risk is the major obstacle to immunotherapy use in liver transplant recipients. Further studies on the potential risk factors of rejection are warranted.